Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sorrento Therpt (SRNE)

Sorrento Therpt (SRNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 716,498
  • Shares Outstanding, K 167,798
  • Annual Sales, $ 21,190 K
  • Annual Income, $ -203,540 K
  • 60-Month Beta 3.01
  • Price/Sales 21.85
  • Price/Cash Flow N/A
  • Price/Book 83.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.37
  • Number of Estimates 1
  • High Estimate -0.37
  • Low Estimate -0.37
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +7.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.11 +37.30%
on 12/26/19
5.09 -16.11%
on 01/10/20
+1.00 (+30.58%)
since 12/24/19
3-Month
1.45 +194.48%
on 11/18/19
5.09 -16.11%
on 01/10/20
+2.76 (+182.78%)
since 10/24/19
52-Week
1.39 +207.19%
on 10/11/19
6.50 -34.31%
on 03/22/19
+2.11 (+97.69%)
since 01/24/19

Most Recent Stories

More News
Growing Demand for Novel Drug Delivery Technologies that Allow Medication to Cross the Blood Brain Barrier

Reports say that the global drug delivery across brain barrier market size is expected to reach USD $4.6 billion by 2026, according to a new report by Grand View Research, Inc. registering a CAGR of 30.2%...

CNSP : 4.40 (-1.12%)
SRNE : 4.27 (+1.91%)
RARE : 56.97 (-0.45%)
VBIV : 1.28 (-0.78%)
PHAS : 5.29 (-8.32%)
Watch for Sorrento Therape to Potentially Pullback After Gaining 39.88% Yesterday

Sorrento Therape (NASDAQ:SRNE) traded in a range yesterday that spanned from a low of $4.41 to a high of $5.09. Yesterday, the shares gained 39.9%, which took the trading range above the 3-day high of...

SRNE : 4.27 (+1.91%)
Thinking about buying stock in Cronos Group, FuelCell Energy, Alphabet, QUALCOMM, or Sorrento Therapeutics?

InvestorsObserver issues critical PriceWatch Alerts for CRON, FCEL, GOOGL, QCOM, and SRNE.

FCEL : 1.82 (+3.41%)
GOOGL : 1,466.17 (-1.25%)
QCOM : 89.65 (-2.55%)
SRNE : 4.27 (+1.91%)
Sorrento Therapeutics, Inc. Received Non-Binding Acquisition Proposal

Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento" or the "Company"), announced today that on January 9, 2020, it received a non-binding proposal from a private equity fund to acquire a majority or...

SRNE : 4.27 (+1.91%)
Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in China

Sorrento Therapeutics (Nasdaq: SRNE) announced today that its partner Mabpharm (HK:2181) filed recently a New Drug Application for the Infliximab biosimilar antibody in China. Sorrento plans to file a...

SRNE : 4.27 (+1.91%)
Sorrento Announces Dr. Robin Smith as New Member of the Board of Directors

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that Robin L. Smith, MD, MBA has been appointed to its Board of Directors.

SRNE : 4.27 (+1.91%)
SEEL : 1.22 (-1.61%)
Thinking about buying stock in Camber Energy, CVS, Dropbox, FuelCell Energy, or Sorrento Therapeutics?

InvestorsObserver issues critical PriceWatch Alerts for CEI, CVS, DBX, FCEL, and SRNE.

CEI : 2.03 (+5.73%)
CVS : 71.43 (-2.86%)
FCEL : 1.82 (+3.41%)
SRNE : 4.27 (+1.91%)
Sorrento Announces New Board Member

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that Mr. Edgar Lee has been appointed to its Board of Directors. Mr. Lee is currently a Managing Director at Oaktree Capital Management....

CHTR : 504.67 (-1.65%)
SRNE : 4.27 (+1.91%)
OCSL : 5.57 (unch)
OCSI : 8.30 (+0.48%)
NEO.TO : 11.10 (-1.86%)
Researchers Leverage CBD's Medical Properties to Fight a Plethora of Ailments

Over the past year, demand for cannabidiol, or CBD, has been increasing at an exponential pace. In particular, the U.S. experienced massive growth in CBD sales after it passed the Farm Bill in late 2018,...

AMBS : 0.0130 (+3.17%)
SRNE : 4.27 (+1.91%)
EMHTF : 0.2510 (-3.83%)
EMH.VN : 0.335 (-2.90%)
PURA : 0.0369 (+0.54%)
MJNA : 0.0212 (-7.83%)
After Yesterday's Rally of 9.59% Shares Could Potentially Pullback

Sorrento Therape (NASDAQ:SRNE) traded in a range yesterday that spanned from a low of $2.94 to a high of $3.28. Yesterday, the shares gained 9.6%, which took the trading range above the 3-day high of...

SRNE : 4.27 (+1.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Trade SRNE with:

Business Summary

Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is focused primarily on the acquisition, discovery, development and commercialization of proprietary oncology therapeutics. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic disease and...

See More

Key Turning Points

2nd Resistance Point 4.41
1st Resistance Point 4.34
Last Price 4.27
1st Support Level 4.15
2nd Support Level 4.03

See More

52-Week High 6.50
Fibonacci 61.8% 4.55
Last Price 4.27
Fibonacci 50% 3.94
Fibonacci 38.2% 3.34
52-Week Low 1.39

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar